Bristol-Myers Squibb Company

Release Summary

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors

Bristol-Myers Squibb Company